All In Biotech

Drug Trial Radar · NCT06059222

The Optimised Use of Romozosumab Study

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Oct 2, 2023

Primary completion

Aug 31, 2030

Study completion Aug 31, 2032

Sponsor

Lead sponsor
University of AarhusAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OPTIMIST is a two-year, randomised, active controlled, open-label, multicentre intervention trial. OPTIMIST includes 3 treatment groups each comprising combinations of romosozumab (ROMO) and zoledronate (ZOL) treatment used in standard doses (210 mg monthly (sc) and 5 mg yearly (iv), respectively). The study will investigate if it is possible to maximize the effect of romosozumab by giving it in 2 periods of 6 months interrupted by zoledronate for 12 months compared to romosozumab for 12 months uninterrupted followed by zoledronate for 12 months. The investigators will also evaluate if 6 months of romosozumab followed by 18 months of zoledronate is non-inferior to the standard regimen of romosozumab for 12 months followed by zoledronate for 12 months.

Conditions

  • Osteoporosis

Interventions

  • RomosozumabDrug

    Romosozumab 210 mg/2.34 ml from baseline to month 11

  • ZoledronateDrug

    5 mg/100 ml at month 12

  • RomosozumabDrug

    210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23

  • ZoledronateDrug

    5 mg/100 ml at month 6

  • RomosozumabDrug

    210 mg/2.34 ml from baseline to month 5

  • ZoledronateDrug

    5 mg/100 ml at month 5 and month 18

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in total hip BMDTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Endrocinology and Internal Medicine

    Aarhus, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.